Please login to the form below

Not currently logged in
Email:
Password:

Alexion

This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy. Also acquires the Swedish group’s lead product for Wilson’s disease. ... Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a $855m offer for rare

Latest news

  • Alexion's Soliris gets US approval for myasthenia gravis Alexion's Soliris gets US approval for myasthenia gravis

    Alexion's Soliris gets US approval for myasthenia gravis. New neurology indication could contribute $1.2bn to sales, says analysts. ... unresolved disease symptoms despite existing treatment options”, according to Alexion’s head of R&D John Orloff.

  • Germany will be first EU launch market for new Soliris indication Germany will be first EU launch market for new Soliris indication

    Alexion 'currently evaluating' additional European launches for its orphan drug. Alexion has won a new European indication for its ultra-orphan drug Soliris (eculizumab) and picked Germany to be its first ... The drug’s new indication will be initially

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    NICE broadens access to Alexion's rare disease drug Strensiq. New deal offers NHS England a discount for the drug. ... NHS and enables people with the highest unmet need to be identified", said a spokesman for Alexion Pharma UK.

  • NICE blocks second Alexion rare disease drug in a week NICE blocks second Alexion rare disease drug in a week

    NICE blocks second Alexion rare disease drug in a week. Says high cost and “ considerable uncertainties” over long-term benefits prohibit routine NHS use. ... Patients with the rare inherited genetic disorder lysosomal acid lipase deficiency (LAL-D)

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    AZ, BMS and Boehringer among UK Prix Galien finalists. They join Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda. ... asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016

More from news
Approximately 20 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • European venture funding for the life science sector European venture funding for the life science sector

    Eli Lilly, Novartis and Alexion, should ensure a healthy M&A appetite going forward.

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)

  • Deal Watch August 2016 Deal Watch August 2016

    This high premium and the one for Cynapsys (see below) has led to speculation that other potential target mid cap biotech companies such as Vertex, BioMarin and Alexion could command higher

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co,

  • Pharma deals in May 2015 Pharma deals in May 2015

    Topping the table with a headline value of $8.4bn was the acquisition of Synageva BioPharma by Alexion. ... With a similar headline value to Synageva/Alexion and building on its acquisition plans was the purchase of Par Pharmaceuticals by Endo.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Abeona Therapeutics names CEO Abeona Therapeutics names CEO

    Abeona Therapeutics names CEO. Carsten Thiel joins the biopharma from Alexion. ... Formerly serving as Alexion Pharmaceutical’s executive vice president and chief commercial officer, Thiel brings experience in leading commercial operations to his new

  • Amryt Pharma appoints Jordi Casals as head of Europe Amryt Pharma appoints Jordi Casals as head of Europe

    Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Alexion Pharmaceuticals adds to its board. Judith Reinsdorf recently worked at Johnson Controls. ... David Brennan, chairman of the board, said: “We are pleased to welcome Judy to Alexion ’s board of directors.

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Alexion appoints new senior VP for EMEAC region. Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. ... Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

More from appointments
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics